GRI Bio presents late-breaking Phase 2a GRI-0621 idiopathic pulmonary fibrosis data at ERS 2026

GRI•2026-08-24

Program positioning

Program positioning centers on a differentiated RARβ/γ-selective mechanism, supporting continued clinical advancement in idiopathic pulmonary fibrosis.

Phase 2a data presented at ERS Congress

GRI Bio flagged new Phase 2a data for oral IPF drug GRI-0621 for future presentation at the ERS Congress on Sept. 6, 2026.

Disclosed outcomes pointed to improved lung function signals, anti-fibrotic biomarker shifts, and favorable tolerability versus placebo.

GRI Bio presents late-breaking Phase 2a GRI-0621 idiopathic pulmonary fibrosis data at ERS 2026

Program positioning

Phase 2a data presented at ERS Congress

Related News

Franklin Limited Duration Income Trust announces annual shareholder meeting

Xpeng forecast disappoints as China EV competition heats up

Saba Capital reports $457,818 ECAT common shares disposal

Capricor rises after US FDA extends review of muscle disorder therapy

Wall Street opens lower as high-stakes Iran, inflation tests loom